Moreover, stem cells, including cancer stem cells, are documented to be resistant to TRAIL [16,19,20], suggesting that without further sensitization of the tumour-initiating cell sub-population, patients are likely to relapse following TRAIL therapy. This evidence concerns the gene TNFSF10 and cancer.